Skip to main content
OGN logo

OGN · Organon & Co. · Documents

Track OGN — free
Market Cap
$3.65B
Shares
262.62M
Volume · Nov 17 4.16M Avg daily vol (3M) 2.71M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $6.22B down 2.9% 10-K filed Feb 24, 2026 Quarterly report FY2026 Q3 Revenue $1.57B down 1.7% 10-Q filed Oct 30, 2026 Latest results Financial results 8-K filed Apr 30, 2026 Earnings call Q4 2025 earnings call Held Feb 12, 2026
2026
Oct 30
Current report 8-K
GAAP net income rose as adjusted earnings declined

Organon & Co. reported GAAP net income of $164 million for the quarter ended September 30, 2026, up from $160 million in 2025, while adjusted net income fell to $256 million from $263 million and adjusted EBITDA declined to $502 million from $518 million.

Regulation FD disclosure
5 source passages
On October 30, 2026, Organon & Co. (the “Company”) released its financial results for the quarter ended September 30, 2026 with the filing of the Company’s Quarterly Report on Form 10-Q (the “Form 10-Q”) with the Securities and Exchange Commission (the “SEC”). Three Months Ended September 30, | 2026 | 2025 | Nine Months Ended September 30, GAAP Reported Net Income | 164 | 160 | 418 | 392 Non-GAAP Adjusted Net Income | 256 | 263 | 674 | 789 Adjusted EBITDA (Non-GAAP) | 502 | 518 | 1,378 | 1,524 Open the document at this passage
Oct 30
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Sun Pharma acquisition priced at $14.00 per share

Organon agreed to sell all outstanding shares to Sun Pharma for $14.00 per share in cash, with closing expected by early 2027. Worldwide sales were $1.6 billion for the three months ended September 30, 2026, down 2%.

Revenue $1.57B ▼ 1.7% Net income $164M ▲ 2.5% Diluted EPS $0.60 ▼ 1.6%
Read from the MD&A section
4 source passages
the possibility that competing offers or acquisition proposals for Organon will be made On April 26, 2026, we entered into a definitive agreement with Sun Pharma under which Sun Pharma will acquire all of our outstanding shares of common stock for $14.00 per share in cash. The transaction is expected to close by early 2027. Worldwide sales were $1.6 billion for the three months ended September 30, 2026, a decrease of 2%, compared to 2025. Open the document at this passage
Jul 31
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $1.56B ▼ 2.3% Net income $108M ▼ 25.5% Diluted EPS $0.40 ▼ 28.6%
Jul 17
Current report 8-K
Other events AI summary on its way
May 4
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $1.46B ▼ 3.5% Net income $146M ▲ 67.8% Diluted EPS $0.55 ▲ 66.7%
Apr 24
Proxy statement DEF 14A Meeting Jun 9, 2026
Proxy statement AI summary on its way
Feb 24
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $6.22B ▼ 2.9% Net income $187M ▼ 78.4% Diluted EPS $0.72 ▼ 78.4%
Feb 20
Current report 8-K
Other events AI summary on its way
2025
Nov 10
Annual report 10-K/A FY2024, ended Dec 31
Annual report for FY2024
Revenue $6.4B ▲ 2.2% Net income $864M ▼ 15.5% Diluted EPS $3.33 ▼ 16.5%
Nov 10
Quarterly report 10-Q FY2025 Q3, ended Sep 30
Quarterly report for FY2025 Q3
Revenue $1.6B ▲ 1.3% Net income $160M ▼ 55.4% Diluted EPS $0.61 ▼ 55.8%
Aug 6
Quarterly report 10-Q FY2025 Q2, ended Jun 30
Quarterly report for FY2025 Q2
Revenue $1.59B ▼ 0.8% Net income $145M ▼ 25.6% Diluted EPS $0.56 ▼ 25.3%
May 2
Quarterly report 10-Q FY2025 Q1, ended Mar 31
Quarterly report for FY2025 Q1
Revenue $1.51B ▼ 6.7% Net income $87M ▼ 56.7% Diluted EPS $0.33 ▼ 57.7%
Feb 28
Annual report 10-K FY2024, ended Dec 31
Annual report for FY2024
Revenue $6.4B ▲ 2.2% Net income $864M ▼ 15.5% Diluted EPS $3.33 ▼ 16.5%
Showing 1–50 of 119 documents
Key facts CIK 1821825 CUSIP 68622V106 13F (30d) 642 filings 554 filers Visit website Investor relations